First Time Loading...
C

Clarus Therapeutics Holdings Inc
NASDAQ:CRXT

Watchlist Manager
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Watchlist
Price: 0.021 USD -19.54% Market Closed
Updated: May 15, 2024

Clarus Therapeutics Holdings Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Clarus Therapeutics Holdings Inc
Interest Income Expense Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
C
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Interest Income Expense
-$15.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$212m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$676m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$1.5B
CAGR 3-Years
130%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$1.2B
CAGR 3-Years
N/A
CAGR 5-Years
-30%
CAGR 10-Years
-13%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$368m
CAGR 3-Years
-133%
CAGR 5-Years
-10%
CAGR 10-Years
-30%

See Also

What is Clarus Therapeutics Holdings Inc's Interest Income Expense?
Interest Income Expense
-15.9m USD

Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Interest Income Expense amounts to -15.9m USD.

What is Clarus Therapeutics Holdings Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-3%

Over the last year, the Interest Income Expense growth was -3%.